TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Antitumor Activity of AG-01 by Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: composite complete remission (CRc) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal distance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTE Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of mature oocytes (MII) retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Manchester-Oxford Foot Questionnaire (MOXFQ) index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of ECG checks successfully conducted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of self-treatments successfully conducted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of matching between Next Generation Sequencing and Standard-of-Care culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Residual Disease (MRD) negative Complete Remission rate by NGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Residual Disease (MRD) negative Complete Remission rate by FDG PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to analgesia postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent HPV infection
Endpoint domain: Adverse events/effects
Primary endpoint: RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination and 28 days post-primary vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of tooth movement for the lower anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Female Sexual Function Index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of COVID-19 Related Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: UE Motor Assessment Scale (UE-MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9 Hole Peg Test (9HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of interno / externo implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin hydration parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Toxicity Criteria for Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual Tension Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days to first relapse of HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intake of total daily amount of meat protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in proportion of meat protein of the total protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Counts of main meals with meat and alternative protein products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Symptoms of Gastroesophageal Reflux Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Index sFlt-1/PIGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daytime mean systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Archery shooting performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain intensity on Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms severity and functional status on Boston Carpal Tunnel Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Automaticity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing in the donor area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root surface closure rate in the recipient area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue thickness in the recipient area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of symptomatic intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage reduction of 24-hour premature atrial beats count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs)/ Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of withdrawals due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in time to complete the grooved peg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of score of the upper extremity portion of the Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline score of the Expanded Disability Status Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time from baseline to complete the timed 25 foot walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in composite disability metric
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of FAAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of MAGL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dementia Knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing Diagnosis Detection Skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Students' perceptions of the effectiveness of learning in a simulation environment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wound healing promotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients completing 3 doses of Sipuleucel-T immunotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects with detectable elevated IgG level and/or T-cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival outcomes of multiple myeloma patients
Endpoint domain: Mortality/survival
Primary endpoint: Concordance for tumor lesion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Straight leg raising test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total oral morphine equivalents consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of c-reactive proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients enrolled in the trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of patients remaining in the trial to completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in social domain of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in emotional domain of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptoms domain of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OPTION score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vitamin K Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Legs dysmetria in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Crowding Relieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death termination
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Concentration of BRV and Its Metabolites After Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Brivaracetam for Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to detect tonicity or volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects with eye abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with COVID-19 Vaccine Hesitancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Foot and ankle Outcome Score (FAOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12 Item Short Form Survey (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Left Ventricular (LV) Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion rate of concurrent chemoradiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Urea Nitrogen (BUN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid thigh circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak indacaterol and glycopyrronium concentration in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hounsfield Unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of Neutrophil Extracellular Traps (NETs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breathlessness Beliefs Questionnaire (Caregiver Version)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HCP confidence in clinical decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient/parent/school confidence in carrying out management guidance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Numbers of subjects with positive IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neutralizing Antibody (NAb) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Treatment-Emergent, Immune-Related, Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Days to Achieve Trophic Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in Physical Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with DLT Event
Endpoint domain: Adverse events/effects
Primary endpoint: Aphasia presence/severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in eating attitudes at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in stress levels at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in depression symptoms at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in anxiety symptoms at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in body weight at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in % total fat mass at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight from pre-procedure to 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hypertension from pre-procedure to 10 years using blood pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in percent value of HgA1c to determine change in diabetes status from pre-procedure to 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-erythrocyte viscosity dispersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rheological profile of red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Osteolysis (bone stock in cm3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin time of the mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activated Partial Thromboplastin Time (APTT) of the mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: COVID Vaccine Uptake at Month 1
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: COVID Vaccine Uptake at Month 3
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean percentage loss of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Charlson index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Circulating Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bush-Francis Catatonia Rating Scale (BFCRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Receiving Each Regimen in Each Line of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of Therapy for Each Regimen
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reasons for Stopping Treatments in Each Line of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Sequencing Pathways
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Receiving Locoregional Treatment for Localized Disease and Metastasis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of somatic mutations in bladder tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain verbal numerical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal infant bonding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: All-cause and cardiac mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative rate of patients with worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of any hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Revised Foot Function Index (FFI-R)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: liver transplant free survival at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in score on the word and vowel recognition test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oswestry Disability Index, version 2.0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence of medication compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: quality of life evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with treatment - patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PTSD symptom checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of signal intensity gradient in aneurysmal sac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CANTAB - Paired Associate Learning test (PAL TEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with perineal tear
Endpoint domain: Adverse events/effects
Primary endpoint: Average infant daily crying and fussing duration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in passive sensitivity discrimination threshold between each hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative HBV-DNA conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Liver hardness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Home Palliative Care Receipt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Expression of genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to negative conversion of COVID-19 infectious viable virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CAV event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment cross over rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Loss to follow up rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in vagina laxity condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vagina tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effect after using the formulation
Endpoint domain: Adverse events/effects
Primary endpoint: Travelled distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of pain during injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain/Numbness Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of symptom severity and functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive function assessment using CDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Tepotinib and Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of postoperative visceral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Adverse Events reported
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distance visual acuity by eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life: emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in quality of life: social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in quality of life: body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Contractility of the muscle at the upper gastrointestinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pressurized metered-dose inhaler (pMDI) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Index of Physical and Social Outcome-Physical scale (SIPSO-P)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning